The present application provides use of a diterpene compound derivative or a salt thereof in the preparation of a medicine for preventing and treating atopic dermatitis. The micromolecular diterpene compound derivative or the salt thereof has a remarkable effect of preventing and treating atopic dermatitis, shows a good prevention and treatment effect on a mouse AD model induced by OXA or MC903, can inhibit the increase of skin lesion score, the thickening of ear thickness, the aggravation of ear swelling and the increase of mast cells in mouse lesion, and also can reduce the IgE concentration of serum and improve the itching degree, indicating that the compound can be used for preventing and treating atopic dermatitis, thereby providing a 10 new prevention and treatment thought and an effective medicine for treatment of atopic dermatitis.
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Provided in the present application are a benzimidazole compound, and a preparation method therefor and the use thereof, wherein the benzimidazole compound has a structure as shown in formula A, has an effect of treating chronic heart failure, and has broad application prospects.
The present application provides use of a diterpene compound derivative or a salt thereof in the preparation of a medicine for preventing and treating atopic dermatitis. The micromolecular diterpene compound derivative or the salt thereof has a remarkable effect of preventing and treating atopic dermatitis, shows a good prevention and treatment effect on a mouse AD model induced by OXA or MC903, can inhibit the increase of skin lesion score, the thickening of ear thickness, the aggravation of ear swelling and the increase of mast cells in mouse lesion, and also can reduce the IgE concentration of serum and improve the itching degree, indicating that the compound can be used for preventing and treating atopic dermatitis, thereby providing a new prevention and treatment thought and an effective medicine for treatment of atopic dermatitis.
The present application relates to a use of (+)-2-borneol in preparation of a drug for treating a cerebral ischemic stroke, wherein an NIHSS score of the cerebral ischemic stroke is greater than or equal to 6. The drug can effectively reduce or avoid serious adverse reactions generated during the prevention and/or treatment of the cerebral ischemic stroke, and improve the prevention and/or treatment effect of the cerebral ischemic stroke.
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
5.
USE OF BORNEOL IN PREPARATION OF DRUG FOR TREATMENT OF CEREBRAL ISCHEMIC STROKE
The present application relates to an application of (+)-2-borneol in the preparation of a drug for treatment of cerebral ischemic stroke, the cerebral ischemic stroke being selected from cerebral strokes having an NIHSS score greater than or equal to 6. The drug can effectively reduce or avoid prevent serious adverse reactions caused in a process of prevention and/or treatment of cerebral ischemic stroke, and improve prevention and/or treatment effects for cerebral ischemic stroke.
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
6.
APPLICATION OF DITERPENE COMPOUND OR SALT THEREOF IN PREPARATION OF MEDICINE FOR PREVENTING AND TREATING ACUTE LUNG INJURY
A diterpene compound or a pharmaceutically acceptable salt thereof in the preparation of a medicine for preventing and treating acute lung injury. The structure of the diterpene compound is as shown in Formula I. The diterpene compound had favorable preventive and therapeutic effects on a mouse model with a lipopolysaccharide-induced acute lung injury, and improved the state of pathological changes of lung tissues in a mouse with an acute lung injury. The compound is capable of reducing damage from pulmonary edema, reducing damage to the lung blood-air barrier, inhibiting the expression of tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), and interleukin 6 (IL-6) in injured lung tissue, and suppressing the infiltration and oxidative stress of neutrophile granulocytes in injured lung tissue.
Provided in the present invention are a phenylpropionate compound, a preparation method for same, and applications. The phenylpropionate compound has the structure as represented by formula I. The phenylpropionate compound of the present invention, a pharmaceutically acceptable salt, a solvate, a prodrug, and a tautomer or stereochemical isomer or pharmaceutical composition of the compound provide improved anti-inflammatory and antiplatelet effects and, at the same time, provide an extended time window for treatment, are free of obvious side effects, safe and effective, applicable in an antithrombus, anti-inflammatory, and cerebral stroke treating medicament, and have broad application prospects.
Glaucocalyxin a derivative, pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof and uses thereof in preparation of drugs for treating psoriasis
A glaucocalyxin A derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof and uses thereof in the preparation of drugs for treating psoriasis.
The present application provides a medicament having an anti-inflammatory bowel disease function, and a preparation method therefor and an application thereof. The medicament has a structure as represented in formula I or formula II. The medicament and a pharmaceutically acceptable salt, a solvate, a prodrug, a tautomer, a stereoisomer, or a pharmaceutical composition thereof provided by the present application have a good effect on inflammatory bowel diseases, can be used for preparing medicaments for treating the inflammatory bowel diseases, and have important clinical significance and wide application prospects.
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
C07C 41/00 - Preparation of ethersPreparation of compounds having groups, groups or groups
C07C 49/517 - Saturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups
C07C 45/29 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation of hydroxy groups
C07C 69/712 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 67/03 - Preparation of carboxylic acid esters by reacting an ester group with a hydroxy group
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
10.
GLAUCOCALYXIN A DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF IN PREPARATION OF DRUGS FOR TREATING PSORIASIS
A glaucocalyxin A derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof and uses thereof in the preparation of drugs for treating psoriasis.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
Provided is a glaucocalyxin A derivative, or salt thereof, as represented by the formula (I), a method for preparation of said glaucocalyxin A derivative, and a use for said glaucocalyxin A derivative in preparing pharmaceuticals for fighting autoimmune diseases and tumors, e.g. difficult-to-treat diseases such as systemic lupus erythematosus, psoriasis and triple-negative breast cancer
A61P 37/00 - Drugs for immunological or allergic disorders
C07C 221/00 - Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
C07C 225/12 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms being part of rings
C07D 207/00 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
C07D 233/60 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
C07D 295/116 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
patents
